☰

Monica L. Guzman, Ph.D. - Publications

Affiliations: 
2002 University of Kentucky, Lexington, KY 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

168 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Di Meo F, Iyer A, Akama K, Cheng R, Yu C, Cesarano A, Kurihara N, Tenshin H, Aljoufi A, Marino S, Soni RK, Roda J, Sissons J, Vu LP, Guzman M, et al. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports. Medicine. 4: 101110. PMID 37467717 DOI: 10.1016/j.xcrm.2023.101110  0.336
2023 Sugita M, Yamazaki T, Alhomoud M, Martinet J, Latouche JB, Golden E, Boyer O, Van Besien K, Formenti SC, Galluzzi L, Guzman ML. Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell Death & Disease. 14: 305. PMID 37142568 DOI: 10.1038/s41419-023-05829-6  0.316
2022 Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, ... ... Guzman ML, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. PMID 36399715 DOI: 10.1182/blood.2022017865  0.304
2022 Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, Yip W, Filipe S, Lebuhotel C, Gouble A, Hassane DC, Smith J, Roboz GJ, Guzman ML. Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nature Communications. 13: 2227. PMID 35484102 DOI: 10.1038/s41467-022-29668-9  0.394
2022 Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, ... ... Guzman ML, et al. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature Communications. 13: 2228. PMID 35484100 DOI: 10.1038/s41467-022-29669-8  0.301
2021 Balandrán JC, Dávila-Velderrain J, Sandoval-Cabrera A, Zamora-Herrera G, Terán-Cerqueda V, García-Stivalet LA, Limón-Flores JA, Armenta-Castro E, Rodríguez-Martínez A, Leon-Chavez BA, Vallejo-Ruiz V, Hassane DC, Pérez-Tapia SM, Ortiz-Navarrete V, Guzman ML, et al. Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL. Frontiers in Immunology. 12: 746492. PMID 34737747 DOI: 10.3389/fimmu.2021.746492  0.368
2021 Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan L, De Leon JP, Croyle JA, Kaner J, Merugu S, Sharma S, MacDonald TY, Noorzad Z, Panchal P, ... ... Guzman ML, et al. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology. 5: 44. PMID 34040147 DOI: 10.1038/s41698-021-00183-2  0.377
2020 Kawabata KC, Zong H, Meydan C, Wyman S, Wouters BJ, Sugita M, Goswami S, Albert M, Yip W, Roboz GJ, Chen Z, Delwel R, Carroll MP, Mason C, Melnick A, ... Guzman ML, et al. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. PMID 32911532 DOI: 10.1182/Blood.2019001745  0.486
2020 Merugu S, Sharma S, Kaner J, Digwal C, Sugita M, Joshi S, Taldone T, Guzman ML, Chiosis G. Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. Methods in Enzymology. 639: 289-311. PMID 32475406 DOI: 10.1016/Bs.Mie.2020.04.057  0.313
2020 Sugita M, Guzman ML. CD123 as a Therapeutic Target Against Malignant Stem Cells. Hematology/Oncology Clinics of North America. 34: 553-564. PMID 32336419 DOI: 10.1016/J.Hoc.2020.01.004  0.45
2020 Hanekamp D, Snel AN, Kelder A, Scholten WJ, Khan N, Metzner M, Irno-Consalvo M, Sugita M, de Jong A, Oude Alink S, Eidhof H, Wilhelm M, Feuring-Buske M, Slomp J, van der Velden VHJ, ... ... Guzman M, et al. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. British Journal of Haematology. PMID 32239670 DOI: 10.1111/Bjh.16594  0.393
2020 MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, Owens B, Liu L, Roboz GJ, Guzman ML, Melnick AM, Wu S, Mason CE. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nature Biotechnology. PMID 31907405 DOI: 10.1038/S41587-019-0329-2  0.377
2020 Gomez-Arteaga A, Mencia-Trinchant N, Tovar AM, Carrillo IO, Laguna AG, Fuller ER, Penafiel CR, Guzman ML, Hassane DC. Abstract C061: Molecular landscape of acute myeloid leukemia in Mexico Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C061  0.302
2019 Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, ... ... Guzman M, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. The Journal of Clinical Investigation. PMID 31855575 DOI: 10.1172/JCI129126  0.422
2019 Bystrom LM, Bezerra DP, Hsu HT, Zong H, Lara-Martínez LA, De Leon JP, Emmanuel M, Méry D, Gardenghi S, Hassane D, Neto CC, Cunningham-Rundles S, Becker MW, Rivella S, Guzman ML. Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. Blood Advances. 3: 3261-3265. PMID 31698457 DOI: 10.1182/Bloodadvances.2018026633  0.521
2019 Yu EY, Cheung IY, Feng Y, Rabie MO, Roboz GJ, Guzman ML, Cheung NV, Lue NF. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. Neoplasia (New York, N.Y.). 21: 689-701. PMID 31128432 DOI: 10.1016/J.Neo.2019.04.002  0.309
2019 Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, et al. Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML. Cancer Discovery. PMID 31076479 DOI: 10.1158/2159-8290.Cd-19-0106  0.393
2019 Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, Yan P, Joshi S, Pagare PP, Bolaender A, Roboz GJ, Guzman ML, Chiosis G. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harbor Perspectives in Biology. PMID 30936118 DOI: 10.1101/Cshperspect.A034116  0.312
2019 Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, Guzman ML. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nature Nanotechnology. PMID 30911166 DOI: 10.1038/S41565-019-0406-1  0.365
2019 Caldas-Lopes E, Gomez-Arteaga A, Guzman ML. Approaches to Targeting Cancer Stem Cells in Solid Tumors. Current Stem Cell Research & Therapy. PMID 30806324 DOI: 10.2174/1574888X14666190222164429  0.375
2019 Bommagani S, Penthala NR, Balasubramaniam M, Kuravi S, Caldas-Lopes E, Guzman ML, Balusu R, Crooks PA. A novel tetrazole analogue of resveratrol is a potent anticancer agent. Bioorganic & Medicinal Chemistry Letters. 29: 172-178. PMID 30528695 DOI: 10.1016/J.Bmcl.2018.12.006  0.352
2019 Kaner JD, Tavakkoli M, Toudic L, Stevens BM, Jordan CT, Taldone T, Chiosis G, Ritchie EK, Desai P, Samuel MB, Lee S, Roboz GJ, Guzman ML. PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71 Blood. 134: 3935-3935. DOI: 10.1182/Blood-2019-128276  0.373
2019 Fay HRS, Dykstra KM, Johnson M, Cronin TL, Lutgen-Dunckley L, Martens BL, Moberg JR, Guzman ML, Wang ES. Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia Blood. 134: 1278-1278. DOI: 10.1182/Blood-2019-127024  0.348
2019 Cai T, Black KL, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Galetto R, Gouble A, Smith JNP, Cavazos A, Han L, Zhang Q, Kuruvilla VM, Ma H, ... ... Guzman ML, et al. Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease Blood. 134: 2659-2659. DOI: 10.1182/Blood-2019-126869  0.351
2019 Caldas Lopes E, Wang T, Jayabalan DS, Taldone T, Monge J, Contreras J, Winnie Y, Trujillo V, Palak P, Lombardi N, Sahil S, Chander D, Coleman M, Chiosis G, Niesvizky R, ... Guzman ML, et al. Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma Blood. 134: 4399-4399. DOI: 10.1182/Blood-2019-125267  0.411
2019 Tavakkoli M, Kaner JD, Sahil S, Taldone T, Merugu S, Chiosis G, Roboz GJ, Guzman ML. Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia Blood. 134: 5145-5145. DOI: 10.1182/Blood-2019-125175  0.351
2018 Gomez-Arteaga A, Guzman ML. Minimal Residual Disease in Acute Myeloid Leukemia. Advances in Experimental Medicine and Biology. 1100: 111-125. PMID 30411263 DOI: 10.1007/978-3-319-97746-1_7  0.398
2018 Wang T, Rodina A, Dunphy MP, Corben A, Modi S, Guzman ML, Gewirth DT, Chiosis G. Chaperome heterogeneity and its implications for cancer study and treatment. The Journal of Biological Chemistry. PMID 30409908 DOI: 10.1074/Jbc.Rev118.002811  0.336
2018 Flores-Lopez G, Moreno-Lorenzana D, Ayala-Sanchez M, Aviles-Vazquez S, Torres-Martinez H, Crooks PA, Guzman ML, Mayani H, Chávez-González A. Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species. Journal of Cellular and Molecular Medicine. PMID 30079458 DOI: 10.1111/Jcmm.13755  0.462
2018 Kourtis N, Lazaris C, Hockemeyer K, Balandrán JC, Jimenez AR, Mullenders J, Gong Y, Trimarchi T, Bhatt K, Hu H, Shrestha L, Ambesi-Impiombato A, Kelliher M, Paietta E, Chiosis G, ... Guzman ML, et al. Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nature Medicine. PMID 30038221 DOI: 10.1038/S41591-018-0105-8  0.343
2018 Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, Roboz GJ, Hassane DC. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature Medicine. 24: 1015-1023. PMID 29988143 DOI: 10.1038/S41591-018-0081-Z  0.312
2018 Roboz GJ, Ritchie EK, Dault Y, Lam L, Marshall DC, Cruz NM, Hsu HC, Hassane DC, Christos PJ, Ippoliti C, Scandura JM, Guzman ML. Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. PMID 29724902 DOI: 10.3324/Haematol.2017.183418  0.421
2018 Bunaciu RP, MacDonald RJ, Gao F, Johnson LM, Varner JD, Wang X, Nataraj S, Guzman ML, Yen A. Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment. Oncotarget. 9: 4134-4149. PMID 29423110 DOI: 10.18632/Oncotarget.23642  0.336
2018 Roboz GJ, Sugita M, Mosquera JM, Wilkes DC, Nataraj S, Jimenez-Flores RA, Bareja R, Yan L, Eng KW, Croyle JA, MacDonald TY, Noorzad Z, Pancirer D, Cheng S, Xiang JZ, ... ... Guzman ML, et al. Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia Blood. 132: 1435-1435. DOI: 10.1182/Blood-2018-99-118764  0.483
2018 Johnson M, Dykstra K, Cronin T, Lutgen-Dunckley L, Martens BL, Guzman ML, Wang ES. Chloroquine Derivative Lys05 Overcomes Hypoxia-Induced Chemoresistance in Acute Myeloid Leukemia through Metabolic Disruption Blood. 132: 3948-3948. DOI: 10.1182/Blood-2018-99-116961  0.321
2018 Han L, Qiu P, Jorgensen JL, Mak D, Burks JK, McQueen T, Zeng Z, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Andreeff M, Guzman ML, Konopleva MY. Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse Blood. 132: 912-912. DOI: 10.1182/Blood-2018-99-111970  0.411
2018 Kaner JD, Mencia-Trinchant N, Schaap A, Roboz GJ, Lee S, Desai P, Samuel M, Krichevsky S, Udoyen I, Hassane DC, Guzman ML, Ritchie EK. Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival Blood. 132: 2760-2760. DOI: 10.1182/Blood-2018-99-110319  0.334
2018 Sugita M, Mencia-Trinchant N, Ewing-Crystal N, Suppa G, Galetto R, Gouble A, Smith J, Roboz GJ, Hassane DC, Guzman ML. Abstract 5681: Prediction of immunotherapy outcome by multimodal assessment of minimal residual disease and persistence of allogeneic anti-CD123 CAR T-cells (UCART123) in pre-clinical models of acute myeloid leukemia Cancer Research. 78: 5681-5681. DOI: 10.1158/1538-7445.Am2018-5681  0.436
2018 Dykstra KM, Hanekamp DW, Johnson M, Guzman ML, Wang ES. Abstract 2864: Inhibition of the late stages of autophagy overcomes hypoxia-induced chemoresistance and targets leukemic stem cells in acute myeloid leukemia Cancer Research. 78: 2864-2864. DOI: 10.1158/1538-7445.Am2018-2864  0.447
2018 Cai T, Black KL, Naqvi A, Galetto R, Gouble A, Smith J, Cavazos A, Han L, Zhang Q, Kuruvilla V, Konoplev SNS, Neelapu SS, Lane AA, Guzman ML, Kantarjian H, et al. Abstract 2560: Preclinical efficacy of allogeneic anti-CD123 CAR T-cells for the therapy of blastic plasmacytoid dendritic cell neoplasm (BPDCN) Cancer Research. 78: 2560-2560. DOI: 10.1158/1538-7445.Am2018-2560  0.397
2017 Li F, He B, Ma X, Yu S, Bhave RR, Lentz SR, Tan K, Guzman ML, Zhao C, Xue HH. Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. Cell Stem Cell. PMID 28844837 DOI: 10.1016/J.Stem.2017.08.001  0.448
2017 Cruz NM, Sugita M, Ewing-Crystal N, Lam L, Galetto R, Gouble A, Smith J, Hassane DC, Roboz GJ, Guzman ML. Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. Leukemia & Lymphoma. 1-5. PMID 28795850 DOI: 10.1182/Blood.V128.22.1693.1693  0.309
2017 Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, Hassane DC, Guzman ML. CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & Lymphoma. 1-8. PMID 28718760 DOI: 10.1080/10428194.2017.1352089  0.324
2017 Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S, Ritchie EK, Desai P, Guzman ML, Roboz GJ, Hassane DC. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. The Journal of Molecular Diagnostics : Jmd. PMID 28525762 DOI: 10.1016/J.Jmoldx.2017.03.005  0.337
2017 Chaudhry P, Singh M, Triche TJ, Guzman M, Merchant AA. GLI3 Repressor Determines Hedgehog Pathway Activation and is Required for Response to SMO Antagonist Glasdegib in AML. Blood. PMID 28487292 DOI: 10.1182/Blood-2016-05-718585  0.422
2017 Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML. Minimal residual disease in acute myelogenous leukemia. International Journal of Laboratory Hematology. 39: 53-60. PMID 28447422 DOI: 10.1111/Ijlh.12670  0.37
2017 Glass J, Hassane DC, Wouters B, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer A, Meydan C, Qin T, Fall MP, Alonso A, Guzman ML, et al. Epigenetic Identity in AML Depends on Disruption of Non-promoter Regulatory Elements and is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery. PMID 28408400 DOI: 10.1158/2159-8290.Cd-16-1032  0.302
2017 Madadi NR, Penthala NR, Ketkar A, Eoff RL, Trujullo-Alonso V, Guzman ML, Crooks PA. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer agents. Anti-Cancer Agents in Medicinal Chemistry. PMID 28403783 DOI: 10.2174/1871521409666170412115703  0.361
2017 Desai P, Mencia-Trinchant N, Oleksandr S, Simon MS, Lee S, Ritchie EK, Guzman ML, Ballman K, Roboz GJ, Hassane DC. Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study Blood. 130: 408-408. DOI: 10.1182/Blood.V130.Suppl_1.408.408  0.345
2017 Cai T, Galetto R, Gouble A, Smith J, Cavazos A, Han L, Zhang Q, Kuruvilla VM, Konoplev SN, Neelapu SS, Lane AA, Guzman ML, Kantarjian HM, Pemmaraju N, Konopleva M. Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Blood. 130: 2625-2625. DOI: 10.1182/Blood.V130.Suppl_1.2625.2625  0.407
2017 Baran N, Han L, Sweeney SR, Lodi A, Herbrich S, Cavazos A, Ma H, Feng N, Chen H, Kaminski M, Dunner K, Tang G, Alatrash G, Molina J, Guzman ML, et al. Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models Blood. 130: 1350-1350. DOI: 10.1182/Blood.V130.Suppl_1.1350.1350  0.406
2017 Shukla S, Gray F, Ying W, Cho H, Zhao Q, Miao H, Purohit T, Guzman M, Grembecka J, Cierpicki T. Abstract 50: Small molecule Ring1B-Bmi1 inhibitor attenuates PRC1 E3 ligase activity and targets leukemia stem cells self-renewal Clinical Cancer Research. 23: 50-50. DOI: 10.1158/1557-3265.Hemmal17-50  0.483
2017 Bai Y, Basciano P, Li X, Matakas J, Giandomenico SD, Sen S, Evans T, Scandura J, Guzman M, Giannakakou P. Abstract 4646: A novel truncated variant of the hematopoietic Hβ-1 tubulin isotype with implications for stem cell biology Cancer Research. 77: 4646-4646. DOI: 10.1158/1538-7445.Am2017-4646  0.396
2017 Baran N, Han L, Herbrich S, Sweeney SR, Lodi A, Gay J, Feng N, Molina JR, Kaminski M, Guzman ML, Al-Atrash G, Tiziani S, Marszalek JR, Konopleva M. Novel Complex I inhibitor IACS-010759 Targets Leukemia Initiating Cells (LICs) in AML Patients Clinical Lymphoma Myeloma and Leukemia. 17: S297. DOI: 10.1016/J.Clml.2017.07.089  0.411
2016 Balandrán JC, Purizaca J, Enciso J, Dozal D, Sandoval A, Jiménez-Hernández E, Alemán-Lazarini L, Perez-Koldenkova V, Quintela-Núñez Del Prado H, Rios de Los Ríos J, Mayani H, Ortiz-Navarrete V, Guzman ML, Pelayo R. Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis. Frontiers in Immunology. 7: 666. PMID 28111575 DOI: 10.3389/Fimmu.2016.00666  0.442
2016 Bystrom LM, Zong H, Martinez L, Neto C, Roboz GJ, Rivella S, Guzman ML. A-type proanthocyanidins selectively target acute myeloid leukemia cells in vitro and in vivo. Planta Medica. 81: S1-S381. PMID 27976147 DOI: 10.1055/S-0036-1596948  0.41
2016 Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, ... ... Guzman ML, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. PMID 27706135 DOI: 10.1038/Nature19807  0.33
2016 Chavez-Gonzalez A, Bakhshinejad B, Pakravan K, Guzman ML, Babashah S. Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cellular Oncology (Dordrecht). PMID 27678246 DOI: 10.1007/S13402-016-0297-1  0.459
2016 Illendula A, Gilmour J, Grembecka J, Tirumala VS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, ... ... Guzman ML, et al. Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. Ebiomedicine. 8: 117-131. PMID 27428424 DOI: 10.1016/J.Ebiom.2016.04.032  0.408
2016 Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. Evolution of acute myelogenous leukemia stem cell properties following treatment and progression. Blood. PMID 27421961 DOI: 10.1182/Blood-2016-02-695312  0.456
2016 Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, ... ... Guzman ML, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine. PMID 27322744 DOI: 10.1038/Nm.4125  0.359
2016 Ordóñez PE, Sharma KK, Bystrom LM, Alas MA, Enriquez RG, Malagón O, Jones DE, Guzman ML, Compadre CM. Dehydroleucodine, a Sesquiterpene Lactone from Gynoxys verrucosa, Demonstrates Cytotoxic Activity against Human Leukemia Cells. Journal of Natural Products. PMID 27057812 DOI: 10.1021/Acs.Jnatprod.5B00383  0.399
2016 Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, ... ... Guzman M, et al. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature Communications. 7: 10739. PMID 26898884 DOI: 10.1038/Ncomms10739  0.449
2016 Guzman ML, Sugita M, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, Lam L, Cruz NM, Galetto R, Gouble A, Hassane DC, Smith J, Roboz GJ. Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts Blood. 128: 765-765. DOI: 10.1182/Blood.V128.22.765.765  0.493
2016 Rapaport F, de Massy MR, al Hinai A, Sanders MA, Hricik T, Sheridan C, Lee TC, Neelamraju Y, Patel J, Chung SS, Becker MW, Lewis ID, D'Andrea R, Bullinger L, Döhner K, ... ... Guzman ML, et al. Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia Blood. 128: 599-599. DOI: 10.1182/Blood.V128.22.599.599  0.382
2016 Cai T, Galetto R, Gouble A, Smith J, Cavazos A, Konoplev S, Lane AA, Guzman ML, Kantarjian HM, Pemmaraju N, Konopleva M. Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Blood. 128: 4039-4039. DOI: 10.1182/Blood.V128.22.4039.4039  0.457
2016 Mencia-Trinchant N, Youssef A, Hu Y, Ali F, Ritchie EK, Guzman ML, Roboz GJ, Hassane DC. Minimal Residual Disease Assessment of Common and Rare NPM1 Mutations Using a Single Massively Multiplex Digital PCR Assay Blood. 128: 2888-2888. DOI: 10.1182/Blood.V128.22.2888.2888  0.347
2016 Samaraweera SE, Garrett-Bakelman FE, Neelamraju Y, Perugini M, Casolari DA, Iarossi D, Bray SC, Sheridan C, Lee TC, Tiong IS, Danner S, Cummings N, Guzman ML, Roboz GJ, To LB, et al. Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML Blood. 128: 2877-2877. DOI: 10.1182/Blood.V128.22.2877.2877  0.353
2016 Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Mohammad H, Smitheman K, Shih AH, Abdel-Wahab O, Paietta E, Tallman MS, Guzman ML, Kruger RG, et al. Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia Blood. 128: 1048-1048. DOI: 10.1182/Blood.V128.22.1048.1048  0.452
2016 Li S, Garrett-Bakelman FE, Chung SS, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Connon J, Sanders MA, Valk PJM, Bullinger L, Luger S, ... ... Guzman ML, et al. Abstract LB-073: Epigenome evolution in relapsed acute myeloid leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-073  0.337
2016 Guzman ML, Zong H, Sugita M, Lara-Martinez LA, Bystrom LM, Cruz NM, Galetto R, Gouble A, Lebuhotel C, Bank A, Smith J, Roboz GJ. Abstract 3992: Allogeneic TCRαβ-deficient CAR T-cells targeting CD123 effectively eliminate myeloid leukemia cells in vitro and in vivo PDX mice Cancer Research. 76: 3992-3992. DOI: 10.1158/1538-7445.Am2016-3992  0.463
2016 Albert M, Sugita M, Zong H, Himanen J, Guzman ML. Abstract 3834: scFv antibodies against EphA2 receptor as a therapeutic strategy for AML Cancer Research. 76: 3834-3834. DOI: 10.1158/1538-7445.Am2016-3834  0.411
2016 Bystrom LM, Lara-Martinez LA, Gomel B, Isal B, Zong H, Martinez S, Neto C, Rivella S, Guzman ML. Abstract 1232: A-type proanthocyanidins selectively target acute myeloid leukemia cells in vitro and in vivo Cancer Research. 76: 1232-1232. DOI: 10.1158/1538-7445.Am2016-1232  0.457
2016 Galetto R, Lebuhotel C, Gouble A, Bank A, Roboz GJ, Guzman ML, Smith J. 397. Allogenic CAR T-Cells Targeting CD123 Effectively Eliminate Myeloid Leukemia Cells Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33206-3  0.44
2015 Zong H, Sen S, Zhang G, Mu C, Albayati ZF, Gorenstein DG, Liu X, Ferrari M, Crooks PA, Roboz GJ, Shen H, Guzman ML. In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia. PMID 26669973 DOI: 10.1038/Leu.2015.343  0.339
2015 Madadi NR, Zong H, Ketkar A, Zheng C, Penthala NR, Janganati V, Bommagani S, Eoff RL, Guzman ML, Crooks PA. Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin. Medchemcomm. 6: 788-794. PMID 26257861 DOI: 10.1039/C4Md00478G  0.354
2015 Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 27: 589-602. PMID 25817203 DOI: 10.1016/J.Ccell.2015.02.016  0.427
2015 Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, Zhou Y, Boulton A, Kuntimaddi A, Gao Y, Rajewski RA, Guzman ML, Castilla LH, Bushweller JH. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Science (New York, N.Y.). 347: 779-84. PMID 25678665 DOI: 10.1126/Science.Aaa0314  0.41
2015 Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 87: 346-56. PMID 25598437 DOI: 10.1002/Cyto.A.22628  0.476
2015 Penthala NR, Zong H, Ketkar A, Madadi NR, Janganati V, Eoff RL, Guzman ML, Crooks PA. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents. European Journal of Medicinal Chemistry. 92: 212-20. PMID 25557492 DOI: 10.1016/J.Ejmech.2014.12.050  0.304
2015 Guzman ML. CDK6 is a regulator of stem cells "Egr" to wake up. Blood. 125: 7-9. PMID 25554744 DOI: 10.1182/Blood-2014-11-609230  0.401
2015 Ho T, Taggart J, Amin E, Xu H, Barlowe T, Perez AR, Tivnan P, Okabe R, Lengner C, Verma A, Roboz GJ, Guzman ML, Leslie CS, Nimer SD, Kharas MG. MSI2 Is Required for Maintaining the Activated Myelodysplastic Syndrome Stem Cell Blood. 126: 714-714. DOI: 10.1182/Blood.V126.23.714.714  0.434
2015 Ho T, Jordan CT, LaMere MW, Ashton JM, O'Dwyer K, Mendler JH, Liesveld JL, Wang ES, Guzman ML, Calvi LM, Becker MW. A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression Blood. 126: 4266-4266. DOI: 10.1182/Blood.V126.23.4266.4266  0.475
2015 Garrett-Bakelman FE, Li S, Chung SS, Hricik T, Franck R, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon BJ, Sanders MA, Valk PJM, Bullinger L, Luger S, ... ... Guzman ML, et al. Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia Blood. 126: 306-306. DOI: 10.1182/Blood.V126.23.306.306  0.385
2015 Zong H, Taldone T, Roboz GJ, Chiosis G, Guzman ML. A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML Blood. 126: 2567-2567. DOI: 10.1182/Blood.V126.23.2567.2567  0.422
2015 Galetto R, Lebuhotel C, Gouble A, Mencia-Trinchant N, Nicole CM, Roboz GJ, Guzman ML, Smith J. TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML) Blood. 126: 2555-2555. DOI: 10.1182/Blood.V126.23.2555.2555  0.42
2015 Salman Z, Balandrán-Juárez JC, Pelayo R, Guzman ML. A Novel Three-Dimensional Co-Culture System to Study Leukemia in the Bone Marrow Microenvironment Blood. 126: 1864-1864. DOI: 10.1182/Blood.V126.23.1864.1864  0.445
2015 Basciano P, Li X, Matakas J, Liu S, Giandomenico SD, Sen S, Evans T, Scandura J, Guzman M, Giannakakou P. Abstract 5096: ALIBI: a novel, truncated tubulin isotype in AML and stem cells Cancer Research. 75: 5096-5096. DOI: 10.1158/1538-7445.Am2015-5096  0.438
2015 Rodina AA, Taldone T, Kang Y, Patel P, Koren J, Yan P, Gomes ED, Yang C, Patel M, Shrestha L, Ochiana S, Maharaj R, Gozman A, Cox M, Erdjument-Bromage H, ... ... Guzman M, et al. Abstract 1733: Development of chemical tools to study the endogenous Hsp70 interactome in malignant cells Cancer Research. 75: 1733-1733. DOI: 10.1158/1538-7445.Am2015-1733  0.381
2015 Zong H, Penthala NR, Sonar VN, Giannakakou P, Roboz GJ, Crooks PA, Guzman ML. Abstract 1667: Targeting acute myelogenous leukemia with novel combrestatin analogs and development of predictors of response Cancer Research. 75: 1667-1667. DOI: 10.1158/1538-7445.Am2015-1667  0.488
2014 Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular Cancer Therapeutics. 13: 1979-90. PMID 24934933 DOI: 10.1158/1535-7163.Mct-13-0963  0.491
2014 Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, ... ... Guzman ML, et al. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. Acs Chemical Biology. 9: 1698-705. PMID 24934503 DOI: 10.1021/Cb500256U  0.327
2014 Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. The Journal of Clinical Investigation. 124: 222-36. PMID 24334453 DOI: 10.1172/Jci66005  0.423
2014 Guzman ML, Allan JN. Concise review: Leukemia stem cells in personalized medicine. Stem Cells (Dayton, Ohio). 32: 844-51. PMID 24214290 DOI: 10.1002/Stem.1597  0.422
2014 Perugini M, Samaraweera SE, Brown AL, Cummings N, Danner S, Tiong IS, Garrett-Bakelman FE, Carroll MP, Becker MW, Chung SS, Park CY, Mason CE, Guzman ML, Levine RL, Melnick AM, et al. The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation Blood. 124: 69-69. DOI: 10.1182/Blood.V124.21.69.69  0.4
2014 Mencia-Trinchant N, Roboz GJ, Carroll MP, Guzman ML, Hassane DC. Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia Blood. 124: 4790-4790. DOI: 10.1182/Blood.V124.21.4790.4790  0.44
2014 Pulikkan JA, Illendula A, Grembecka J, Xue L, Rajewski R, Guzman ML, Bushweller JH, Castilla LH. Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML Blood. 124: 390-390. DOI: 10.1182/Blood.V124.21.390.390  0.505
2014 Salman Z, Leon JPD, Feldman EJ, Burrows F, Roboz GJ, Guzman ML. In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents Blood. 124: 3765-3765. DOI: 10.1182/Blood.V124.21.3765.3765  0.473
2014 Allan JN, Jayabalan D, Niesvizky R, Mark TM, Pearse R, Rossi AC, Tegnestam L, Hassane DC, Guzman ML. Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF Blood. 124: 2452-2452. DOI: 10.1182/Blood.V124.21.2452.2452  0.339
2014 Allan JN, Roboz GJ, Feldman EJ, Scandura JM, Ritchie EK, Lam L, Xie W, Hsu H, Hassane DC, Guzman ML. Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Blood. 124: 1041-1041. DOI: 10.1182/Blood.V124.21.1041.1041  0.318
2014 Velu CS, Chaubey A, Phelan JD, Meyer S, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, et al. Abstract 979: microRNA-mediated leukemia-initiating cell activity Cancer Research. 74: 979-979. DOI: 10.1158/1538-7445.Am2014-979  0.418
2014 Sturgill EM, Guzman ML. Abstract 4793: The M2 isoform of pyruvate kinase (PKM2) contributes to leukemia stem cell persistence by maintaining oxidative homeostasis and promoting glycolysis Cancer Research. 74: 4793-4793. DOI: 10.1158/1538-7445.Am2014-4793  0.443
2013 Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental Hematology. 41: 799-807.e4. PMID 23660068 DOI: 10.1016/J.Exphem.2013.04.012  0.386
2013 Carlson KS, Guzman ML. Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia? Current Hematologic Malignancy Reports. 8: 109-15. PMID 23563936 DOI: 10.1007/S11899-013-0157-2  0.32
2013 Felipe Rico J, Hassane DC, Guzman ML. Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer Letters. 338: 4-9. PMID 22713929 DOI: 10.1016/J.Canlet.2012.05.034  0.478
2013 Roboz GJ, Scandura JM, Ritchie E, Dault Y, Lam L, Xie W, Hsu H, Marshall D, Christos PJ, Ippoliti C, Feldman EJ, Guzman ML. Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML Blood. 122: 621-621. DOI: 10.1182/Blood.V122.21.621.621  0.381
2013 Sturgill EM, Guzman ML. Cytokine Induced Nuclear Localization Of Pyruvate Kinase M2 In Acute Myeloid Leukemia Blood. 122: 5406-5406. DOI: 10.1182/Blood.V122.21.5406.5406  0.446
2013 Bystrom LM, Zong H, Hsu H, Yang N, Greenberg N, Wang Q, Neto C, Guo M, Rivella S, Guzman ML. A-Type Proanthocyanidins Prevent Engraftment Of Primary Acute Myelogenous Leukemia Cells In Mice and Exhibit Potentially Novel Anti-Leukemia Mechanisms Blood. 122: 3962-3962. DOI: 10.1182/Blood.V122.21.3962.3962  0.483
2013 Garrett-Bakelman FE, Li S, Hricik T, Chung SS, Bar H, Brown AL, Patel JP, Rapoport F, Liu L, Sheridan C, Ishii J, Zumbo P, Gandara J, Lewis ID, To LB, ... ... Guzman ML, et al. Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia Blood. 122: 2499-2499. DOI: 10.1182/Blood.V122.21.2499.2499  0.382
2013 Han L, Zeng Z, Qiu P, Jorgensen JL, Mak DH, Burks JK, McQueen T, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-Cell Mass Cytometry Reveals Phenotypic and Functional Heterogeneity In Acute Myeloid Leukemia At Diagnosis and In Remission Blood. 122: 1311-1311. DOI: 10.1182/Blood.V122.21.1311.1311  0.395
2012 Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, ... ... Guzman ML, et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discovery. 2: 1004-23. PMID 23107779 DOI: 10.1158/2159-8290.Cd-12-0208  0.388
2012 Bystrom L, Hsu H, Neto C, Roboz GJ, Hassane DC, Rivella S, Guzman ML. A-Type Proanthocyanidins From Cranberries Target Acute Myelogenous Leukemia Stem Cells. Blood. 120: 2986-2986. DOI: 10.1182/Blood.V120.21.2986.2986  0.508
2012 Zong H, Sen S, Zhang G, Gorenstein DG, Liu X, Ferrari M, Roboz GJ, Shen H, Guzman ML. Novel Multistage Nanoparticle Drug Delivery to Ablate Leukemia Stem Cells in Their Niche. Blood. 120: 2631-2631. DOI: 10.1182/Blood.V120.21.2631.2631  0.449
2012 Sharma KK, Rico JF, Becker MW, Roboz GJ, Chiosis G, Guzman ML. HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML). Blood. 120: 2476-2476. DOI: 10.1182/Blood.V120.21.2476.2476  0.388
2012 Rodina A, Moulick K, Ahn J, Zong H, Cerchietti L, DaGama EG, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu L, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Guzman M, et al. Abstract 3029: Biochemical evidence towards the existence of an oncogenic Hsp90 complex Cancer Research. 72: 3029-3029. DOI: 10.1158/1538-7445.Am2012-3029  0.416
2012 Gomes-DaGama EM, Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Lopes-Vazquez MEC, Beebe K, Perna F, Katerina C, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Guzman ML, et al. Abstract 1263: Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 Cancer Research. 72: 1263-1263. DOI: 10.1158/1538-7445.Am2012-1263  0.354
2011 Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Guzman ML, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/Nchembio.670  0.375
2011 Nasim S, Guzman ML, Jordan CT, Crooks PA. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. Bioorganic & Medicinal Chemistry Letters. 21: 4879-83. PMID 21757349 DOI: 10.1016/J.Bmcl.2011.06.027  0.432
2011 Taldone T, Zatorska D, Patel PD, Zong H, Rodina A, Ahn JH, Moulick K, Guzman ML, Chiosis G. Design, synthesis, and evaluation of small molecule Hsp90 probes. Bioorganic & Medicinal Chemistry. 19: 2603-14. PMID 21459002 DOI: 10.1016/J.Bmc.2011.03.013  0.313
2011 Zong H, Taldone T, Ahn JH, Brennan S, De Leon JP, Becker MW, Roboz GJ, Chiosis G, Guzman ML. FLT3-ITD+ AML Blast, Progenitor and Stem Cell Populations Demonstrate Higher Sensitivity to the Hsp90 Inhibitor PU-H71, Blood. 118: 3500-3500. DOI: 10.1182/Blood.V118.21.3500.3500  0.474
2011 Zong H, Penthala NR, Sen S, Brennan S, Sonar V, Crooks PA, Guzman ML. The Acrylonitrile Analog, VJ-289 Ablates Acute Myelogenous Leukemia Blast, Progenitor and Stem Cell Populations by Inducing Tubulin Acetylation and Caspase Activation Blood. 118: 2496-2496. DOI: 10.1182/Blood.V118.21.2496.2496  0.485
2011 Rico JF, Sharma KK, Kang Y, Taldone T, Patel H, Brennan S, Zong H, Becker MW, Roboz GJ, Chiosis G, Guzman ML. HSP70 Inhibitor, YK5, Ablates Blast, Progenitor and Stem Cell Populations in Primary Acute Myelogenous Leukemia Cells Blood. 118: 2493-2493. DOI: 10.1182/Blood.V118.21.2493.2493  0.519
2011 Hassane DC, Leon JPD, Corbett C, Rossi RM, Xie W, Jordan CT, Guzman ML. Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction Blood. 118: 1885-1885. DOI: 10.1182/Blood.V118.21.1885.1885  0.382
2011 Xie W, Hassane DC, Jordan CT, Roboz GJ, Guzman ML. High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin Blood. 118: 1430-1430. DOI: 10.1182/Blood.V118.21.1430.1430  0.398
2011 Sen S, Leon JPD, Smith PG, Roboz GJ, Guzman ML. Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, MLN4924, Demonstrates Activity Against Primary AML Blast, Progenitor and Stem Cell Populations Blood. 118: 1414-1414. DOI: 10.1182/Blood.V118.21.1414.1414  0.47
2011 Sharma KK, Rico JF, Hassane DC, Chiosis G, Guzman ML. Dysregulated Expression of HSP70 Isoforms in Acute Myelogenous Leukemia (AML) Blood. 118: 1370-1370. DOI: 10.1182/Blood.V118.21.1370.1370  0.429
2011 Rodina A, Kang Y, Taldone T, Patel H, Patel P, Caldas-Lopes E, Erdjument-Bromage H, Guzman M, Young JC, Melnick A, Chiosis G. Abstract 2579: YK5, a small molecule inhibitor of Hsp70 and Hsc70, reveals a multifaceted role for the Hsp70 chaperones in regulating oncogenic and non-oncogenic addiction of tumors Cancer Research. 71: 2579-2579. DOI: 10.1158/1538-7445.Am2011-2579  0.367
2011 Yang N, Hassane DC, Balys M, Corbett CA, Jordan CT, Guzman ML. Abstract 2145: AR-42, a novel histone deacetylase inhibitor with selectivity against leukemia stem cell via apoptosis induction, inhibition of chaperone function of heat shock protein 90 in acute myeloid leukemia Cancer Research. 71: 2145-2145. DOI: 10.1158/1538-7445.Am2011-2145  0.479
2010 Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 116: 5983-90. PMID 20889920 DOI: 10.1182/Blood-2010-04-278044  0.416
2010 Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology. 151: 70-83. PMID 20701602 DOI: 10.1111/J.1365-2141.2010.08319.X  0.447
2010 Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Zeleznik-Le N, Jordan CT, Carroll M, Gebelein B, Grimes HL. Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance Blood. 116: 4192-4192. DOI: 10.1182/Blood.V116.21.4192.4192  0.4
2009 Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: Seek and destroy Expert Review of Hematology. 2: 663-672. PMID 21082958 DOI: 10.1586/Ehm.09.53  0.477
2009 Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, Bernstein SH. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. Plos One. 4: e8115. PMID 19956548 DOI: 10.1371/Journal.Pone.0008115  0.42
2009 Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorganic & Medicinal Chemistry Letters. 19: 4346-9. PMID 19505822 DOI: 10.1016/J.Bmcl.2009.05.092  0.338
2009 Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, et al. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 23: 1587-97. PMID 19440216 DOI: 10.1038/Leu.2009.99  0.472
2009 Guzman ML, Jordan CT. Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. Cancer Cell. 15: 252-4. PMID 19345324 DOI: 10.1016/J.Ccr.2009.03.008  0.404
2009 Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Risner L, Zeleznik-Le NJ, Jordan CT, Carroll M, Gebelein B, Grimes HL. Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation. Blood. 114: 3966-3966. DOI: 10.1182/Blood.V114.22.3966.3966  0.392
2009 Hassane D, Sen S, Corbett CA, Balys M, Rossi RM, Crooks PA, Guzman ML, Jordan CT. Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide. Blood. 114: 388-388. DOI: 10.1182/Blood.V114.22.388.388  0.488
2009 Skalska J, Brookes PS, Nadtochy SM, Hilchey S, Jordan CT, Guzman ML, Maggirwar S, Briehl MM, Bernstein SH. Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma. Blood. 114: 3774-3774. DOI: 10.1182/Blood.V114.22.3774.3774  0.435
2009 Guzman ML, Nasim S, Balys M, Corbett CA, Crooks PA, Jordan CT. Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity. Blood. 114: 3764-3764. DOI: 10.1182/Blood.V114.22.3764.3764  0.449
2009 Pei S, Guzman ML, Nasim S, Shi L, Crooks PA, Jordan CT. Analysis of the Anti-Leukemia Mechanism of Parthenolide. Blood. 114: 2734-2734. DOI: 10.1182/Blood.V114.22.2734.2734  0.46
2009 Hassane D, Balys M, Marcucci G, Byrd JC, Jordan CT, Guzman ML. Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML). Blood. 114: 2070-2070. DOI: 10.1182/Blood.V114.22.2070.2070  0.471
2008 Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111: 5654-62. PMID 18305216 DOI: 10.1182/Blood-2007-11-126003  0.454
2008 Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 111: 4681-9. PMID 18227347 DOI: 10.1182/Blood-2007-11-125278  0.346
2008 Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Sen S, Guzman ML, Jordan CT, Hsi ED, Abo A. CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML Blood. 112: 4003-4003. DOI: 10.1182/Blood.V112.11.4003.4003  0.498
2008 Hassane DC, Ashton JM, Guzman ML, Jordan CT. Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans. Blood. 112: 3349-3349. DOI: 10.1182/Blood.V112.11.3349.3349  0.449
2008 Howard D, Liesveld J, Phillips GL, Guzman ML, Jordan CT. A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML) Blood. 112: 2953-2953. DOI: 10.1182/Blood.V112.11.2953.2953  0.348
2007 Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 110: 4427-35. PMID 17804695 DOI: 10.1182/Blood-2007-05-090621  0.488
2007 Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 110: 4436-44. PMID 17785584 DOI: 10.1182/Blood-2007-05-088815  0.511
2007 Hassane DC, Guzman ML, Corbett C, Li X, Liesveld JL, Young F, Carroll M, Jordan CT. A Search of Public Gene Expression Microarray Data Identifies Novel Agents That Selectively Eradicate AML Stem Cells. Blood. 110: 776-776. DOI: 10.1182/Blood.V110.11.776.776  0.461
2006 Jordan CT, Guzman ML, Noble M. Cancer stem cells. The New England Journal of Medicine. 355: 1253-61. PMID 16990388 DOI: 10.1056/Nejmra061808  0.374
2006 Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone. 39: 485-93. PMID 16647886 DOI: 10.1016/J.Bone.2006.03.002  0.381
2006 Hassane DC, Guzman ML, Li X, Corbett C, Jordan CT. Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death. Blood. 108: 2592-2592. DOI: 10.1182/Blood.V108.11.2592.2592  0.476
2006 Guzman ML, Li X, Corbett C, Rossi RM, Bushnell T, Jordan CT. Rapid Loss of Membrane Integrity and Irreversible Commitment to Cell Death of Primary AML Stem Cells: A Novel Activity for 4-benzyl, 2-methyl,1,2,4-Thiadiazolidine,3,5 Dione (TDZD-8). Blood. 108: 2535-2535. DOI: 10.1182/Blood.V108.11.2535.2535  0.497
2006 Guzman ML, Rossi RM, Li X, Corbett C, Hassane DC, Bushnell T, Carroll M, Sullivan E, Neelakantan S, Crooks PA, Jordan CT. A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells. Blood. 108: 237-237. DOI: 10.1182/Blood.V108.11.237.237  0.503
2005 Guzman ML, Jordan CT. Feverfew: weeding out the root of leukaemia. Expert Opinion On Biological Therapy. 5: 1147-52. PMID 16120045 DOI: 10.1517/14712598.5.9.1147  0.476
2005 Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 105: 4163-9. PMID 15687234 DOI: 10.1182/Blood-2004-10-4135  0.51
2005 Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Molecular and Cellular Biology. 25: 1100-12. PMID 15657436 DOI: 10.1128/Mcb.25.3.1100-1112.2005  0.308
2005 Guzman ML, Li X, Corbett C, Hassane DC, Jordan CT. Mechanisms Controlling Selective Death of Leukemia Stem Cells in Response to Parthenolide. Blood. 106: 467-467. DOI: 10.1182/Blood.V106.11.467.467  0.469
2005 Rossi RM, Henn AD, Conkling R, Guzman ML, Bushnell T, Harvey J, Fisher RI, Jordan CT. The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells. Blood. 106: 1483-1483. DOI: 10.1182/Blood.V106.11.1483.1483  0.412
2004 Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 23: 7178-87. PMID 15378078 DOI: 10.1038/Sj.Onc.1207935  0.441
2004 Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 11: 97-104. PMID 15024346 DOI: 10.1177/107327480401100216  0.481
2004 Guzman ML, Karnischky L, Li X, Neering SJ, Rossi RM, Jordan CT. Selective Induction of Apoptosis in Acute Myelogenous Leukemia Stem Cells by the Novel Agent Parthenolide. Blood. 104: 2542-2542. DOI: 10.1182/Blood.V104.11.2542.2542  0.513
2004 Calvi LM, Weber JM, Guzman ML, Christianson CA, Milner LM, Jordan CT. Osteoblastic Cells and the Hematopoietic Microenvironment: The Notch ligand Jagged1 Is Increased in Osteoblastic Stromal Cells by Parathyroid Hormone (PTH)Treatment. Blood. 104: 1284-1284. DOI: 10.1182/Blood.V104.11.1284.1284  0.462
2002 Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT. Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 16220-5. PMID 12451177 DOI: 10.1073/Pnas.252462599  0.49
2001 Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 98: 2301-7. PMID 11588023 DOI: 10.1182/Blood.V98.8.2301  0.456
2001 Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 97: 2177-9. PMID 11264190 DOI: 10.1182/Blood.V97.7.2177  0.454
2000 Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 14: 1777-84. PMID 11021753 DOI: 10.1038/Sj.Leu.2401903  0.39
Show low-probability matches.